#今日行業(yè)熱點(diǎn)#

?

①Nature：The next generation of coronavirus vaccines: a graphical guide

下一代冠狀病毒疫苗圖解指南
②Gut：Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer

YTHDF1可增強(qiáng)結(jié)直腸癌的抗腫瘤免疫并增強(qiáng)抗PD-1的療效

DOI :10.1136/gutjnl-2022-328845

③Journal of Medical Virology：Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity

橫斷面分析揭示了與COVID-19嚴(yán)重程度相關(guān)的自身抗體特征，自身抗體或?yàn)樽陨砻庖咝约膊〉臐撛谥委煱悬c(diǎn)

DOI :10.1002/jmv.28538

④Gut：Inflammation-associated gut microbiome in postacute sequelae of SARS-CoV-2 points towards new therapeutic targets

長(zhǎng)期COVID-19中與炎癥相關(guān)腸道微生物群指向了新的治療靶點(diǎn)

DOI :10.1136/gutjnl-2022-328757

⑤Translational Neurodegeneration：Links between COVID-19 and Parkinsons disease/Alzheimers disease: reciprocal impacts, medical care strategies and underlying mechanisms

COVID-19與帕金森病/阿爾茨海默病之間的聯(lián)系:相互影響、醫(yī)療策略和潛在機(jī)制

DOI :10.1186/s40035-023-00337-1

⑥EMBO Molecular Medicine：Targetable Brg1-CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking

靶向Brg1-CXCL14軸通過(guò)驅(qū)動(dòng)中性粒細(xì)胞轉(zhuǎn)運(yùn)參與酒精性肝損傷

DOI :10.15252/emmm.202216592

⑦達(dá)雷妥尤單抗生物類(lèi)似藥HLX15(重組抗CD38全人單克隆抗體注射液）在中國(guó)男性健康受試者中開(kāi)展的1期臨床研究完成首例受試者給藥

⑧注射用ADC藥物SHR-A1811臨床試驗(yàn)獲批，開(kāi)展用于HER2低表達(dá)乳腺癌治療的臨床試驗(yàn)

⑨重組人促甲狀腺激素（rhTSH）用于分化型甲狀腺癌術(shù)后輔助放射性碘清甲治療以及術(shù)后輔助診斷的兩個(gè)適應(yīng)癥III期臨床研究進(jìn)展順利

⑩全球首個(gè)經(jīng)FDA、EMA批準(zhǔn)，擁有CLDT、ITP雙適應(yīng)癥的血小板生成素受體激動(dòng)劑（TPO- RA）馬來(lái)酸阿伐曲泊帕片申報(bào)獲CDE受理

?

科學(xué)探索的世界充滿(mǎn)挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴(lài)的合作伙伴！